Pharnext Reports First Half 2022 Financial Results
yahoo.com
news
2022-10-17 07:30:00

On-schedule completion of patient enrollment in pivotal Phase III clinical study of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth disease type 1A (‘CMT1A') with top-line results expected in Q4 2023

New data from the ongoing open-label Phase III extension study of PXT3003, the PLEO-CMT-FU trial, shows sustained treatment benefit in patients with CMT1A

Post-period € 20.7 million financing agreement with Néovacs to further advance the development of PXT3003 in CMT1A

PARIS, FRANCE / ACCESSWIRE / October 17, 2022 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces its financial results for the first half of 2022.
